zoledronic acid has been researched along with Cancer, Second Primary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameratunga, R; Chiu, W; Oei, P; Pullon, H; The, R; Woon, ST | 1 |
| Missotten, G; Verheezen, Y | 1 |
| Barrett-Lee, PJ; Bell, R; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Davies, C; Dodwell, D; Gil, M; Grieve, RJ; Houston, SJ; Keane, M; Thorpe, H; Woodward, E | 1 |
| Suzuki, K | 1 |
1 review(s) available for zoledronic acid and Cancer, Second Primary
| Article | Year |
|---|---|
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
1 trial(s) available for zoledronic acid and Cancer, Second Primary
| Article | Year |
|---|---|
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Osteonecrosis; Treatment Outcome; Zoledronic Acid | 2011 |
2 other study(ies) available for zoledronic acid and Cancer, Second Primary
| Article | Year |
|---|---|
IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin E; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Prednisone; Zoledronic Acid | 2010 |
Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Conjunctivitis, Acute Hemorrhagic; Diphosphonates; Humans; Imidazoles; Inflammation; Male; Neoplasms, Second Primary; Neurofibroma; Orbital Diseases; Orbital Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2010 |